MedTrace Logo

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

NCT04668352 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1024

Last updated 2021-06-23

Study results available
· View outcomes & findings →

Summary

To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.

Conditions

  • Respiratory Tract Infections

Interventions

DRUG

Dactolisib

TORC1 inhibitor

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Restorbio Inc.

    lead INDUSTRY

Principal Investigators

  • Dean Quinn, MD · P3 Research Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2019-12-02
Completion
2019-12-02
FDA Drug
Yes

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04668352 on ClinicalTrials.gov